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Genetic factors contribute to anorexia nervosa (AN); and the first genome-wide significant locus 
has been identified. We describe methods and procedures for the Anorexia Nervosa Genetics 
Initiative (ANGI), an international collaboration designed to rapidly recruit 13,000 individuals 
with AN as well as ancestrally matched controls. We present sample characteristics and the 
utility of an online eating disorder diagnostic questionnaire suitable for large-scale genetic and 
population research.  
Methods 
ANGI recruited from the United States (US), Australia/New Zealand (ANZ), Sweden (SE), and 
Denmark (DK). Recruitment was via national registers (SE, DK); treatment centers (US, ANZ, 
SE, DK); and social and traditional media (US, ANZ, SE). All cases had a lifetime AN diagnosis 
based on DSM-IV or ICD-10 criteria (excluding amenorrhea). Recruited controls had no lifetime 
history of disordered eating behaviors. To assess the positive and negative predictive validity of 
the online eating disorder questionnaire (ED100K-v1), 109 women also completed the Structured 
Clinical Interview for DSM-IV (SCID), Module H.  
Results 
Blood samples and clinical information were collected from 13,364 individuals with lifetime AN 
and from controls. Online diagnostic phenotyping was effective and efficient; the validity of the 
questionnaire was acceptable.  
Conclusions 
Our multi-pronged recruitment approach was highly effective for rapid recruitment and can be 












rendered the Internet/social media a remarkably effective recruitment tool in some countries. 
ANGI has substantially augmented Psychiatric Genomics Consortium AN sample collection. 
ANGI is a registered clinical trial: clinicaltrials.gov NCT01916538; 
https://clinicaltrials.gov/ct2/show/NCT01916538?cond=Anorexia+Nervosa&draw=1&rank=3. 
Keywords: anorexia nervosa; eating disorders; genome-wide association; psychiatric genetics; 














AN anorexia nervosa 
ANGI Anorexia Nervosa Genetics Initiative 
ANGI-ANZ(AUS) Study recruitment for Australia/New Zealand from Australia 
ANGI-ANZ(NZ) Study recruitment for Australia/New Zealand from New Zealand 
ANGI-DK Study recruitment for Denmark from the national register and biobank system 
ANGI-DK(clinic) Study recruitment for Denmark from the Danish Psychiatric Biobank 
ANGI-SE(Community) Study recruitment for Sweden from the community 
ANGI-SE(LifeGene) Study recruitment for Sweden from the LifeGene study 
ANGI-SE(Riksät) Study recruitment for Sweden from the Riksät-National Quality Register 
for Eating Disorders Treatment 
ANGI-SE(SCÄ) Study recruitment for Sweden from the Stockholm Centre for Eating 
Disorders 
ANGI-US Study recruitment for the United States 
ANGI-US(PFCG) Study recruitment for the United States from The Price Foundation Study 
AN Trios Study 
ANZ Australia/New Zealand 
CHDS Christchurch Health and Development Study 
DK – Denmark 
DNSB The Danish Neonatal Screening Biobank 
DSM-5 Diagnostic and Statistical Manual of Mental Disorders, 5
th
 edition 
DSM-IV Diagnostic and Statistical Manual of Mental Disorders, 4
th
 edition 












GWAS genome-wide association studies 
iPsych The Lundbeck Initiative for Integrative Psychiatric Research 
PGC Psychiatric Genomics Consortium 
PGC-ED Eating Disorders Working Group of the Psychiatric Genomics Consortium 
PKU phenylketonuria 
RUCDR Rutgers University Cell and DNA Repository 
SCID Structured Clinical Interview for DSM-IV 
SE Sweden 
UNC University of North Carolina at Chapel Hill 

















Genetic factors play a substantial role in liability to anorexia nervosa (AN). Relative risk 
is ~11 in female first-degree relatives of those who have AN (1), and twin studies estimate 
heritability at 48%-74% (2-5). The Eating Disorders Working Group of the Psychiatric 
Genomics Consortium (PGC-ED) reported the first genome-wide significant locus on 
chromosome 12 in a region previously implicated in type 1 diabetes and autoimmune illnesses 
(6). The goal of the Anorexia Nervosa Genetics Initiative (ANGI) was to rapidly expand 
available samples for genome-wide association studies (GWAS) of AN. Given the complex 
genetic architecture of psychiatric disorders, large sample sizes, perhaps hundreds of thousands, 
are necessary to identify variants associated with these disabling conditions (7, 8). We provide an 
overview of recruitment procedures and methods used in ANGI, which collected the largest 
sample of AN cases and controls in the world, considerably augmenting existing samples in the 
PGC-ED (9). 
A secondary goal of ANGI was to provide efficient phenotyping for future investigations. 
In the absence of biomarkers for psychiatric disorders, the large sample sizes required for GWAS 
encourage the development of valid assessments with minimal investment of time and effort. 
Structured clinical interviews, regarded by some as the preferred method for assessing eating 
disorders (10), are not economically feasible for such studies. Well-validated and easily 
accessible self-report assessments provide an alternative and may encourage greater openness 
about disordered eating behaviors than face-to-face interviews (11, 12). To this end, we report 
the validity of an online eating disorder questionnaire (ED100K-v1) designed to capture AN 












information about the etiology of AN and contribute to the development of biologically informed 
therapeutics. 
 
Materials and Methods 
Collaborative Arrangements 
ANGI is an international collaboration sponsored by the Klarman Family Foundation and 
the National Institute of Mental Health. Four primary hubs for data collection, selected because 
of experience in collecting large genetic samples and access to individuals with a lifetime history 
of AN, included the University of North Carolina at Chapel Hill [(UNC), United States (US)]; 
QIMR Berghofer Medical Research Institute [Brisbane, Australia with assistance from the 
University of Otago in Christchurch, New Zealand (ANZ)]; Karolinska Institutet [Stockholm, 
Sweden (SE)]; and Aarhus University [Aarhus, Denmark (DK)].  The organizational structure 
consists of a lead principal investigator (Bulik); site principal investigators (Bulik, Martin, 
Landén, Mortensen); deputy director (Thornton); steering committee (chair: Bulik); biological 
sample committee (chair: Sullivan); analysis group (chair: Sullivan); phenotype group (chair: 
Thornton); and publication and editorial committee (chair: Bulik). A scientific advisory council 
provided external oversight of study procedures; monitored progress of sample collection, 
genotyping, and data analysis; and insured adherence to ethical standards and data sharing 
procedures. The appropriate ethics or institutional review boards at each location approved study 
protocols. 
General Study Procedures 
 In the US, ANZ, and SE, inclusion criteria for cases were based on the Diagnostic and 
Statistical Manual of Mental Disorders, 4
th












Amenorrhea (Criterion D) was not required since it is not applicable to males and was removed 
from the DSM-5. In DK, cases were defined as any individual present in the national patient 
register or who presented in the clinic with an ICD-10 diagnosis of F50.0 (AN) or F50.1 
(atypical AN). 
 Recruitment and study procedures varied across sites (see Figure 1) due to local ethical 
requirements or the manner in which cases were identified and are discussed below.  
United States and Australia/New Zealand  
Recruitment Approach 
A primary focus of our recruitment strategy was to include individuals who: 1) may not 
live close to recruitment centers, but who desired to participate; 2) may have suffered from AN 
and never received treatment; 3) have become detached from providers; or 4) are currently in 
treatment programs. Therefore, we used traditional and novel approaches in the US (ANGI-US) 
and ANZ [ANGI-ANZ(AUS) and ANGI-ANZ(NZ)]. Recruitment avenues included social and 
electronic media; eating disorders treatment centers; posts on Recovery Record (a mobile app for 
individuals in recovery from their eating disorder); prominent eating disorder blogs; and 
traditional media (e.g., newspaper advertisements and flyers). In the US, ANZ, and SE, 
television and radio interviews were conducted and website interviews were posted online, 
which were followed-up on social media sites (e.g., Facebook, Twitter) with links to additional 
stories. The highly successful Australian media campaign was awarded a commendation in the 
Public Relations Institute of Australia Queensland Awards for Excellence.  
Collecting recruitment information regarding how participants heard about the study (US, 
ANZ) allowed us to evaluate the relative effectiveness of recruitment strategies for cost-effective 












wide variety of sources, our sample reflects a broad range of individuals who have had AN and 
not just those seeking treatment. This is critically important as only 33% of individuals with AN 
receive treatment for the illness (13, 14). 
Study Procedures 
Individuals who resided in the US (ages ≥12 years), AUS (ages ≥13 years), or NZ (ages 
≥14) either self-identified or were referred to the study. In the US, individuals first completed an 
online screener to determine study eligibility. In all three countries, those who were interested in 
study participation (and deemed eligible by the brief screen in the US) completed the consent 
process and online questionnaire based on the Structured Clinical Interview for the DSM-IV 
(SCID) (15) Module H (eating disorders). Core diagnostic questions from the SCID-Module H 
were adapted for self-report for ANGI (ED100K-v1) to capture information on lifetime history 
of eating disorders. Once the questionnaire was completed, the participant provided a blood 
sample (see DNA Sampling). 
Controls assessed for ANGI-US were included in the study if they had no lifetime history 
of any disordered eating behavior and did not meet any criteria for cases. Additional control 
samples were obtained from The Price Foundation Study AN Trios Study (16, 17) [ANGI-
US(PFCG)]. Female controls, ages 18-65 years at assessment, were matched to ANGI-US cases 
by ancestry. Control women were required to have lifetime adult minimum body mass index 
(BMI; weight [kilograms] / height
2
 [meters]) > 19 and maximum BMI < 27. They had no history 
of an eating disorder or disordered eating behaviors, nor any first-degree relative with an eating 
disorder.  
In Australia, data from 17,158 participants from the QSkin Sun and Health Study (18) 












ANZ(AUS). This study, focusing on skin cancer and its risk factors, is being conducted by the 
Population Health Department at QIMR (PI: David Whiteman). It uses an electoral roll sample 
of Queenslanders ages 40-60 years (19). Eating disorders are included in the disease checklist: 
controls with no history of eating disorders were selected. Consent for QSkin allows for 
inclusion in other research studies. Additional information about recruitment and study 
procedures from the ANGI-ANZ(AUS) hub is described elsewhere (20).  
Potential controls for participants from New Zealand were made available by the 
Christchurch Health and Development Study (CHDS, 
http://www.otago.ac.nz/christchurch/research/healthdevelopment/) (21), a longitudinal study of 
individuals born in 1977. Controls were selected based on negative responses to a self-report 
eating disorders screen and availability of genotype information (N=739). 
Sweden  
 Recruitment Approach 
Four recruitment strategies were used for ANGI-SE. 1) Individuals in Riksät-National Quality 
Register for Eating Disorders Treatment (22) [ANGI-SE(Riksät)], which includes eating disorder 
information from individuals seeking treatment for an eating disorder in Sweden since 1999, who 
had been in treatment for AN, bulimia nervosa, or eating disorder not otherwise specified were 
sent a letter asking them to complete a follow-up questionnaire, which included the ED100K-v1 
questionnaire. 2) Study nurses at the Stockholm Centre for Eating Disorders [ANGI-SE(SCÄ)] 
recruited cases. A research nurse discussed the study and reviewed the consent process with 
patients with AN who came into the center. When participants consented, a blood sample was 
taken and the participant was directed to complete the ED100K-v1 questionnaire. 3) We 












Swedish ANGI website (www.angi.se), directly linking to the questionnaire [ANGI-
SE(Community)]. 4) Cases and controls were identified in LifeGene (23) [ANGI-SE(LifeGene), 
https://www.lifegene.se/], an ongoing study initiated in 2010 to evaluate how genes, 
environment, and lifestyle affect health. Individuals who enrolled in LifeGene completed an 
eating disorder assessment similar to the ED100K-v1 questionnaire and provided a blood 
sample. Algorithms for case and control identification using the LifeGene eating disorder 
assessment were harmonized with the ED100K-v1 questionnaire.  
Study Procedures 
From ANGI-SE(Riksät), potential cases (ages 15-80 years), willing to participate in 
research and identified by meeting ANGI case criteria from the ED100K-v1 questionnaire or 
with a clinical AN diagnosis, were contacted by a research nurse and invited to participate. If 
interested, they were sent informed consent papers, a phlebotomy kit, and instructions on how to 
donate blood at a local laboratory. Cases from ANGI-SE(Community) were contacted by a 
research nurse and followed the same procedure as Riksät-based recruitment.  
Statistics Sweden provided new, population-based controls [ANGI-SE(Community)] who 
were matched to cases from ANGI-SE(Riksät) on age and sex. Identified individuals were asked 
about height and weight history, eating disorder history, and history of other psychiatric 
disorders. Those who had no lifetime history of an eating disorder and agreed to be in the study 
were sent a blood kit to provide a DNA sample. An additional 3,000 archived control samples 















The primary recruitment approach for ANGI in DK (ANGI-DK) utilized the national 
register and biobank system. Every person who has had permanent residence or was born in 
Denmark since April 1, 1968 is assigned a unique person identifier used across all Danish social 
and health care services. This information can be employed to determine lifetime AN diagnoses 
based on contacts with the hospital system and can be linked to additional registers. Moreover, 
phenylketonuria (PKU) cards from birth are stored for all individuals in The Danish Neonatal 
Screening Biobank (DNSB) at the Staten Serum Institut in Copenhagen and indexed by the 
personal number (see DNA Sampling). PKU cards for individuals who met inclusion criteria and 
for controls were extracted from DNSB. Additional samples [ANGI-DK(Clinic)] were obtained 
from the Danish Psychiatric Biobank that recruits individuals with mental disorders for genetic 
studies (24). The biobank holds DNA samples and demographic, familial, and clinical 
information, including complete records of all hospital in- and out-patient admissions and 
diagnoses.  
Study Procedures 
All cases and controls (birth years 1981-2005) from DK registers were identified from 
the national patient register. ANGI-DK controls were selected from DNSB (24) based on date of 
birth, sex, and absence of major psychiatric disorders.  
For ANGI-DK(Clinic), cases were defined as patients with at least one recorded hospital 
admission resulting in the assignment of an ICD-10 diagnosis of F50.0 or F50.1. Clinic cases 
were women born 1947-1980 (age range: 35-68 years). 
DNA Sampling 
For ANGI-US, ANGI-ANZ, and ANGI-SE, each new participant provided blood samples 












a mobile phlebotomy company, UNC, a local laboratory, or a physician’s office. Samples were 
mailed directly to the National Institute of Mental Health designated laboratory at Rutgers 
University Cell and DNA Repository (RUCDR), where DNA extraction occurred. Sample 
collection procedures for ANGI-US(PFCG) are described elsewhere (25). 
For ANGI-ANZ(AUS), blood draws occurred in community phlebotomy centers. A 
prepaid, addressed consignment note for overnight delivery was included. All kits were returned 
to QIMR for processing. For ANGI-ANZ(NZ), participants across New Zealand first provided 
witnessed informed consent. They were then sent blood kits which they took to a preferred 
phlebotomy center where samples were drawn and sent through the national laboratory courier 
system to Christchurch. Whole blood samples were stored in a tissue bank prior to sending to 
QIMR to be sent with the ANGI-ANZ(AUS) samples to RUCDR for DNA extraction. 
Oragene saliva samples were collected for controls from QSkin. Samples were genotyped 
at Erasmus University on the Illumina Global Screening Array (GSA) chip. Since all cases had 
DNA samples extracted from blood and all controls had DNA extracted from saliva, we 
genotyped DNA from both blood and saliva from 107 cases to compare call rates. Of these, 102 
samples from blood and 101 samples from saliva (100 overlapping samples) passed genotyping 
quality tests. The genotypes from blood and saliva are concordant an average of 99.69% of the 
time for a given person (257,712 tested markers).  
Participants in the CHDS provided either peripheral blood (92%) or Oragene saliva (8%) 
during interviews in 2005. Genotyping of these samples was previously carried out using 
Illumina 660W Quad chips (26). 
For ANGI-SE (Riksät, SCÄ, Community), newly recruited cases and controls provided 












SE(LifeGene) samples from cases and controls were also stored at Karolinska Institutet biobank. 
DNA was extracted at Karolinska Institutet. 
For ANGI-US, ANGI-ANZ, and ANGI-SE, all DNA was sent to the Broad Institute for 
genotyping on the Illumina GSA chip. 
For ANGI-DK, DNA from blood spots (which can be linked to other Danish databases 
discussed above) from birth on all participants were was extracted from two biobanks at the 
Staten Serum Institut in Copenhagen. The first biobank is the DNSB, which collects blood spots 
from all children born in Denmark for the purpose of neonatal screening for PKU and other 
diseases in the newborn (27). The second biobank contains maternal serum samples drawn 
during week 16 of pregnancy for approximately 20% of the DNSB. Prior research demonstrated 
that the amplified DNSB sample results are of as high quality as results from conventionally 
isolated DNA samples for both GWAS genotyping and direct sequencing (28, 29). DNA was 
sent to the Broad Institute for genotyping on the Illumina PsychArray; 3,769 control samples 
were genotyped as part of ANGI-DK. Data for the remaining control samples and for 224 cases 
were supplied by the Lundbeck Initiative for Integrative Psychiatric Research (iPsych) 
consortium (24) and were genotyped at the same time and on the same platform as those for 
ANGI-DK. The ANGI-DK(Clinical) DNA samples were extracted from whole blood samples 
and sent to the Broad for genotyping on the Illumina GSA chip.  
Validity of the Online Eating Disorder Questionnaire (ED100K-v1) 
To assess the validity of the ED100K-v1 questionnaire, we completed follow-up phone 
interviews using the SCID-Module H with a random subsample of ANGI participants who 
agreed to recontact from ANGI-US and ANGI-ANZ(AUS). The validity sample included 52 












removed from analyses because the highest, not the lowest, weight was reported in the SCID-H. 
Interviews were conducted by a PhD-level clinician or interviewer with experience administering 
structured and semi-structured psychiatric diagnostic interviews. All interviewers were trained to 
SCID criteria by a certified PhD-level clinician from the UNC Assessment Core. Training 
included reviewing SCID protocol and instructions, observing SCID interviews, reviewing 
video/audio taped interviews to score, and being observed completing a SCID interview by a 




Statistical analyses were conducted using SAS version 9.3 (30). The significance level for 
all analyses was set to p<.05. We present the percentage of participants who heard about ANGI 
through each source and temporal data on enrollment relative to media launches. We evaluated 
the extent to which individuals enrolled from clinics differed in lowest illness-related BMI and 
age at lowest BMI from those in the community, in the US, using t-tests. We examined the 
construct validity for the online diagnostic questionnaire with the interview-based SCID by 
calculating the positive and negative predictive values for AN Criteria B and C, and for the 
presence of binge eating. Higher values correspond to increased accuracy of results. 
Furthermore, correlations for lowest illness-related BMI and age at low weight were calculated. 
Results are provided by country.  
Results 
General ANGI Descriptive Information 
                                                 
1
 In Australia, the interviewer reviewed the SCID protocol and instructions, observed SCID interviews, and reviewed 
existing interviews with staff from the US. Although the interviewer was not observed administering a SCID by a 
PhD-level clinician in the United States, this individual did have nearly 15 years of experience administering 












Table 1 provides information regarding the number of cases and controls by site and 
source. Only those samples that passed quality control to be submitted for genotyping are 
included.  
 
Evaluation of Recruitment Sources 
 Details about where participants heard about ANGI in the US are provided in Figure 2. 
The most successful recruitment avenue for cases was the Internet, including social media, 
whereas, for controls, it was email followed by the Internet. Advocacy groups and clinicians 
(including clinical programs and eating disorder centers) were also important for recruiting 
cases. More than 20% of controls heard about ANGI through ResearchMatch (a not-for-profit 
online recruitment tool) or UNC (but not via email). Notably, 12% of cases and 13% of controls 
heard about ANGI from family members.  
Figure 3 demonstrates the importance of using media outlets for participant recruitment. 
Although ANGI participation had increased steadily in Australia between the media launches in 
April 2013 and in March 2015, there was a tremendous spike in interest and study completion 
after the second launch. In approximately 2 months, the number of individuals who completed 
the ED100K-v1 questionnaire went from 2,228 to 3,574 individuals. Similarly, Figure 4 
illustrates the impact of media launches for ANGI-ANZ(NZ) recruitment. 
We also explored whether cases from eating disorder treatment centers were significantly 
more ill than individuals from the community in the US. Cases ascertained through the 
community reported a significantly younger age at lowest weight [mean(sd)=17.4 (5.7)] than 
those recruited through eating disorders clinics [mean(sd)=19.5 (9.9); t-value=-2.23, p=.028]. 












disorders clinics [mean(sd)=14.2 (2.1)] having lower lowest illness-related BMIs than those from 
the community [mean(sd)=15.1 (1.9); t-value=-4.75, p<.0001]. However, the majority of 
participants in both groups, 82.8% from eating disorder clinics and 63.3% from the community, 
reported illness-related BMI values consistent with severe and extreme DSM-5 AN severity 
indices. 
 
Validity of Online Eating Disorder Questionnaire 
Table 2 lists the construct validity results. Positive predictive values were high in both 
countries, indicating that among those who had a positive screening test, the probability of AN 
Criterion B, Criterion C, and binge eating ranged from 85% to 100%. Results also indicated that 
among women who had a negative screening test, the probability of not having these AN criteria 
or binge eating was between 77% and 100%. For AUS, all participants endorsed Criterion C in 
the ED100K-v1 questionnaire and all but one individual endorsed Criterion C in the interview; 
thus, we could not calculate negative predictive value. 
The correlations between the ED100K-v1 questionnaire and interview responses for 
lowest illness-related BMI were high (US: r=0.91, AUS: r=0.92; z-score=-0.31, p=.74)). The 
correlation for age at lowest weight in the US (r=0.58) was lower than that for AUS (r=0.90; z-
score=-3.98, p<.0001). In the US, the mean (SD) difference for age at lowest weight between the 
questionnaire and interview was 7.0 (10.7) years; three individuals reported a lower lifetime 















The primary goal of ANGI was to inform the etiology of AN by amassing the largest 
genetic sample of AN ever assembled and creating data and sample resources for future research. 
To accomplish this, we combined new and existing resources from the US, ANZ, SE, and DK. 
Although methods varied across countries, we were successful in ascertaining broadly 
representative cases and controls.  
Our approaches optimized resources in each country. The existence of national patient 
registers (SE and DK) and quality registers (SE) facilitated identification of individuals who had 
been treated for AN (cases) as well as controls. The carefully curated biobank of PKU cards in 
DK made for a highly efficient ascertainment strategy, but precluded re-contacting participants 
for future research. The ability to link both the Swedish and Danish data to other national 
registers will allow us to expand analyses to include a broad range of phenotypes and exposures 
and even design gene-by-environment interaction investigations that include measured 
genotypes. 
The majority of both clinic- and community-ascertained cases had illness-related BMIs in 
the DSM-5 severe and extreme ranges. However, those recruited via clinics reported older ages 
at low weight and somewhat lower illness-related BMIs than cases from the community. 
Notably, some cases from the community reported lowest BMI values that were lower than the 
range observed for those from the clinic. These observations are encouraging for general 
community recruitment for psychiatric genetics—at least for disorders in which there is strong 
social media presence. Although the percentage of individuals recruited via social media who 
had not received treatment is unknown, it raises ongoing concerns that many individuals with 












We were also able to provide information on the appropriateness of using a web-based 
diagnostic questionnaire for ascertainment of cases. ED100K-v1 operationalizes the DSM-IV 
criteria for all eating disorders (now adapted for DSM-5). The questionnaire was comparable to 
the SCID eating disorders module in determining the presence of criteria B and C for AN and in 
assessing lowest illness-related BMI and age at low weight in both the US and AUS. Given the 
need for large samples for successful GWAS, efficient case identification and minimally 
adequate phenotyping are methodologically important (7). A self-report questionnaire based on a 
structured interview that accurately identifies cases reduces the time and money spent on clinical 
interviewing and streamlines the case identification and ascertainment process. 
ANGI does have limitations. First, ANGI participants are primarily of European ancestry 
First, ANGI participants are primarily of European ancestry. The extent to which these GWAS 
results can be generalized to populations of different ancestry is an important direction for future 
science. Second, AN primarily afflicts females. The small number of males recruited limits our 
capacity to determine sex differences in genetic effects. Future studies will require targeted 
strategies to ascertain and recruit substantial numbers of males. Third, ANGI used several 
ascertainment strategies to maximize recruitment in the shortest possible time. This could have 
led to the different sets of cases having different genetic architectures. However, the experience 
of the PGC (and other groups) provides strong evidence that, if this is true, the adverse impact is 
small relative to the large benefits of an increased sample (7, 32). Finally, the SE and DK 
collections enable linkage with other national registers that can provide a comprehensive 
characterization of psychiatric and somatic comorbidity, whereas these auxiliary data are not 












In summary, the ability to generate large sample sizes for genomic investigations on 
eating disorders and other psychiatric disorders requires multi-site and international 
collaborations, as has been successfully demonstrated with the Wellcome Trust Case Control 
Consortium (33) and the PGC (6). The ANGI data are undergoing rigorous quality control and 
are being meta-analyzed with existing PGC-ED data. The combined sample size is approaching 
20,000 cases with ancestrally matched controls, which should yield additional genome-wide 
signals.  
Given the high prevalence of comorbid psychopathology in AN and eating disorders 
more broadly (13, 34, 35), these data can also be used for cross-disorder meta-analyses and SNP-
based genetic correlations to identify putative genetic variants shared with other psychiatric and 
genetically influenced phenotypes. Moreover, an accurate and cost-efficient approach to case and 
control identification through self-report online questionnaires or existing national patient 
registers demonstrated here, is critical for rapid sample acquisition. Although ANGI was a highly 
successful collaboration, even larger sample sizes must be obtained to maximize GWAS 
findings. Ongoing collections from Europe and Asia are queued for genotyping, and large 
collections for other eating disorders (bulimia nervosa and binge-eating disorder) are underway. 
The PGC blueprint for the future aims for 100,000 cases for all major disorders is a scientifically 
justifiable aim (8). Uncovering the biological basis of eating disorders will aid in our 
understanding of their etiology, contribute to the development of novel or repurposed 
therapeutics, and ultimately reduce disability and mortality associated with the illnesses. 
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Figure 1. Case recruitment procedures and study design for the Anorexia Nervosa Genetics 
Initiative (ANGI) by site. 
Figure 2. Sources of recruitment in the United States.  
Figure 3. ANGI-ANZ(AUS) cumulative sample collection: progress after two media launches in 
Australia (April 2013 and March 2015). 
Figure 4. ANGI-ANZ(NZ) cumulative sample collection: progress after two media launches in 




Table 1. The number of samples collected and submitted for genotyping for ANGI, by site and 
source. 





























































































































TOTAL  13,362 42,634    
 
Note: ANGI = Anorexia Nervosa Genetics Initiative; US = United States; ANZ = Australia and 
New Zealand; SE = Sweden; DK = Denmark; PFCG = Price Foundation Control Group; NZ = 
New Zealand; QSkin = QSkin Sun and Health Study; CHDS = Christchurch Health and 
Development Study; SCÄ = Stockholm Center for Eating Disorders; iPsych = Integrative 













Table 2. Positive and negative predictive value (PV) of the ANGI online eating disorder 
questionnaire compared with the SCID-Module H (eating disorders). 
 United States (n = 51) Australia (n = 58) 
 Positive PV Negative PV Positive PV Negative PV 
AN Criterion B 1.00 1.00 0.96 1.00 
AN Criterion C 0.98 1.00 0.98 --- 
Binge Eating 0.85 0.77 0.93 0.83 
 
Note: ANGI = Anorexia Nervosa Genetics Initiative; SCID = Structured Clinical Interview for 
the Diagnostic and Statistical Manual of Mental Disorders-IV; AN = anorexia nervosa. Criterion 
B is an intense fear of gaining weight or becoming fat, even though underweight. Criterion C is a 
marked disturbance in the way body weight or shape is experienced, undue influence of body 
weight or shape on self-evaluation, or denial of the seriousness of current low body weight. 
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